Adaptimmune Therapeutics plc
ADAP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 195.3% | 122% | 341.5% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 100% | 83.6% | -370.5% | -1,706.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -29.6% | -212.7% | -573.1% | -2,531.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -39.8% | -188.9% | -609.5% | -2,571% |
| EPS Diluted | -0.28 | -0.57 | -1.02 | -1.02 |
| % Growth | 50.9% | 44.1% | 0% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |